NCT05098249View on ClinicalTrials.gov

Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia

PHASE4CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

May 9, 2023

Study Completion Date

May 23, 2023

Conditions
AnemiaIron-deficiencyHypophosphatemia
Interventions
DRUG

Verum

The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.

DRUG

Placebo

The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.

Trial Locations (1)

8091

University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

University of Zurich

OTHER

lead

Donat R. Spahn

OTHER

NCT05098249 - Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia | Biotech Hunter | Biotech Hunter